-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Avidity Biosciences, Lowers Price Target to $68

Benzinga·05/12/2025 11:43:49
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and lowers the price target from $72 to $68.